Following news this morning that a Phase III study of Poniard Pharma's (Nasdaq: PARD) picoplatin did not meet its survival ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE